Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD

Attilio Olivieri, Michele Cimminiello, Paolo Corradini, Nicola Mordini, Roberta Fedele, Carmine Selleri, Francesco Onida, Francesca Patriarca, Enzo Pavone, Silvia Svegliati, Armando Gabrielli, Paola Bresciani, Roberta Nuccorini, Sara Pascale, Sabrina Coluzzi, Fabrizio Pane, Antonella Poloni, Jacopo Olivieri, Pietro Leoni, Andrea Bacigalupo

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Forty adults aged 28 to 73 years were entered into a prospective trial of imatinib for the treatment of steroid-refractory chronic graft-versus-host disease (SR-cGVHD). After 6 months, intention-to-treat (ITT) analysis of 39 patients who received the drug, regardless of the duration of treatment, revealed 14 partial responses (PR), 4 minor responses (MR) with relevant steroid sparing (46%) according to Couriel criteria, and 20 ≥ PR (51.3%), as per the National Institutes of Health (NIH) criteria and NIH severity score changes. The best responses were seen in the lungs, gut, and skin (35%, 50%, and 32%, respectively). After a median follow-up of 40 months, 28 patients were alive, with a 3-year overall survival (OS) and event-free survival of 72% and 46%, respectively. The 3-year OS was 94% for patients responding at 6 months and 58% for nonresponders according to NIH response, suggesting that these criteria represent a reliable tool for predicting OS after second-line treatment. Monitoring of anti-platelet-derived growth factor receptor (PDGF-R) antibodies showed a significant decrease in PDGF-R stimulatory activity in 7 responders, whereas it remained high in 4 nonresponders. This study confirms the efficacy of imatinib against SR-cGVHD and suggests that the response at 6 months significantly predicts long-term survival.

Original languageEnglish
Pages (from-to)4111-4118
Number of pages8
JournalBlood
Volume122
Issue number25
DOIs
Publication statusPublished - Dec 12 2013

Fingerprint

National Institutes of Health (U.S.)
Refractory materials
Platelet-Derived Growth Factor Receptors
Steroids
Health
Grafts
Survival
Graft vs Host Disease
Intention to Treat Analysis
Skin
Disease-Free Survival
Therapeutics
Antibodies
Monitoring
Pharmaceutical Preparations
Lung
Imatinib Mesylate

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. / Olivieri, Attilio; Cimminiello, Michele; Corradini, Paolo; Mordini, Nicola; Fedele, Roberta; Selleri, Carmine; Onida, Francesco; Patriarca, Francesca; Pavone, Enzo; Svegliati, Silvia; Gabrielli, Armando; Bresciani, Paola; Nuccorini, Roberta; Pascale, Sara; Coluzzi, Sabrina; Pane, Fabrizio; Poloni, Antonella; Olivieri, Jacopo; Leoni, Pietro; Bacigalupo, Andrea.

In: Blood, Vol. 122, No. 25, 12.12.2013, p. 4111-4118.

Research output: Contribution to journalArticle

Olivieri, A, Cimminiello, M, Corradini, P, Mordini, N, Fedele, R, Selleri, C, Onida, F, Patriarca, F, Pavone, E, Svegliati, S, Gabrielli, A, Bresciani, P, Nuccorini, R, Pascale, S, Coluzzi, S, Pane, F, Poloni, A, Olivieri, J, Leoni, P & Bacigalupo, A 2013, 'Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD', Blood, vol. 122, no. 25, pp. 4111-4118. https://doi.org/10.1182/blood-2013-05-494278
Olivieri, Attilio ; Cimminiello, Michele ; Corradini, Paolo ; Mordini, Nicola ; Fedele, Roberta ; Selleri, Carmine ; Onida, Francesco ; Patriarca, Francesca ; Pavone, Enzo ; Svegliati, Silvia ; Gabrielli, Armando ; Bresciani, Paola ; Nuccorini, Roberta ; Pascale, Sara ; Coluzzi, Sabrina ; Pane, Fabrizio ; Poloni, Antonella ; Olivieri, Jacopo ; Leoni, Pietro ; Bacigalupo, Andrea. / Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. In: Blood. 2013 ; Vol. 122, No. 25. pp. 4111-4118.
@article{131d68dc81a34db2bae68638237a7fc2,
title = "Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD",
abstract = "Forty adults aged 28 to 73 years were entered into a prospective trial of imatinib for the treatment of steroid-refractory chronic graft-versus-host disease (SR-cGVHD). After 6 months, intention-to-treat (ITT) analysis of 39 patients who received the drug, regardless of the duration of treatment, revealed 14 partial responses (PR), 4 minor responses (MR) with relevant steroid sparing (46{\%}) according to Couriel criteria, and 20 ≥ PR (51.3{\%}), as per the National Institutes of Health (NIH) criteria and NIH severity score changes. The best responses were seen in the lungs, gut, and skin (35{\%}, 50{\%}, and 32{\%}, respectively). After a median follow-up of 40 months, 28 patients were alive, with a 3-year overall survival (OS) and event-free survival of 72{\%} and 46{\%}, respectively. The 3-year OS was 94{\%} for patients responding at 6 months and 58{\%} for nonresponders according to NIH response, suggesting that these criteria represent a reliable tool for predicting OS after second-line treatment. Monitoring of anti-platelet-derived growth factor receptor (PDGF-R) antibodies showed a significant decrease in PDGF-R stimulatory activity in 7 responders, whereas it remained high in 4 nonresponders. This study confirms the efficacy of imatinib against SR-cGVHD and suggests that the response at 6 months significantly predicts long-term survival.",
author = "Attilio Olivieri and Michele Cimminiello and Paolo Corradini and Nicola Mordini and Roberta Fedele and Carmine Selleri and Francesco Onida and Francesca Patriarca and Enzo Pavone and Silvia Svegliati and Armando Gabrielli and Paola Bresciani and Roberta Nuccorini and Sara Pascale and Sabrina Coluzzi and Fabrizio Pane and Antonella Poloni and Jacopo Olivieri and Pietro Leoni and Andrea Bacigalupo",
year = "2013",
month = "12",
day = "12",
doi = "10.1182/blood-2013-05-494278",
language = "English",
volume = "122",
pages = "4111--4118",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "25",

}

TY - JOUR

T1 - Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD

AU - Olivieri, Attilio

AU - Cimminiello, Michele

AU - Corradini, Paolo

AU - Mordini, Nicola

AU - Fedele, Roberta

AU - Selleri, Carmine

AU - Onida, Francesco

AU - Patriarca, Francesca

AU - Pavone, Enzo

AU - Svegliati, Silvia

AU - Gabrielli, Armando

AU - Bresciani, Paola

AU - Nuccorini, Roberta

AU - Pascale, Sara

AU - Coluzzi, Sabrina

AU - Pane, Fabrizio

AU - Poloni, Antonella

AU - Olivieri, Jacopo

AU - Leoni, Pietro

AU - Bacigalupo, Andrea

PY - 2013/12/12

Y1 - 2013/12/12

N2 - Forty adults aged 28 to 73 years were entered into a prospective trial of imatinib for the treatment of steroid-refractory chronic graft-versus-host disease (SR-cGVHD). After 6 months, intention-to-treat (ITT) analysis of 39 patients who received the drug, regardless of the duration of treatment, revealed 14 partial responses (PR), 4 minor responses (MR) with relevant steroid sparing (46%) according to Couriel criteria, and 20 ≥ PR (51.3%), as per the National Institutes of Health (NIH) criteria and NIH severity score changes. The best responses were seen in the lungs, gut, and skin (35%, 50%, and 32%, respectively). After a median follow-up of 40 months, 28 patients were alive, with a 3-year overall survival (OS) and event-free survival of 72% and 46%, respectively. The 3-year OS was 94% for patients responding at 6 months and 58% for nonresponders according to NIH response, suggesting that these criteria represent a reliable tool for predicting OS after second-line treatment. Monitoring of anti-platelet-derived growth factor receptor (PDGF-R) antibodies showed a significant decrease in PDGF-R stimulatory activity in 7 responders, whereas it remained high in 4 nonresponders. This study confirms the efficacy of imatinib against SR-cGVHD and suggests that the response at 6 months significantly predicts long-term survival.

AB - Forty adults aged 28 to 73 years were entered into a prospective trial of imatinib for the treatment of steroid-refractory chronic graft-versus-host disease (SR-cGVHD). After 6 months, intention-to-treat (ITT) analysis of 39 patients who received the drug, regardless of the duration of treatment, revealed 14 partial responses (PR), 4 minor responses (MR) with relevant steroid sparing (46%) according to Couriel criteria, and 20 ≥ PR (51.3%), as per the National Institutes of Health (NIH) criteria and NIH severity score changes. The best responses were seen in the lungs, gut, and skin (35%, 50%, and 32%, respectively). After a median follow-up of 40 months, 28 patients were alive, with a 3-year overall survival (OS) and event-free survival of 72% and 46%, respectively. The 3-year OS was 94% for patients responding at 6 months and 58% for nonresponders according to NIH response, suggesting that these criteria represent a reliable tool for predicting OS after second-line treatment. Monitoring of anti-platelet-derived growth factor receptor (PDGF-R) antibodies showed a significant decrease in PDGF-R stimulatory activity in 7 responders, whereas it remained high in 4 nonresponders. This study confirms the efficacy of imatinib against SR-cGVHD and suggests that the response at 6 months significantly predicts long-term survival.

UR - http://www.scopus.com/inward/record.url?scp=84891318859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891318859&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-05-494278

DO - 10.1182/blood-2013-05-494278

M3 - Article

VL - 122

SP - 4111

EP - 4118

JO - Blood

JF - Blood

SN - 0006-4971

IS - 25

ER -